dexamethasone + fosaprepitant + granisetron

This is a three-drug antiemetic combination used primarily to prevent chemotherapy-induced nausea and vomiting (CINV). The combination has been studied in clinical trials for patients receiving highly emetogenic chemotherapy, particularly in breast cancer patients receiving anthracycline and cyclophosphamide (AC-based) regimens. The combination works through complementary mechanisms: dexamethasone (a corticosteroid), fosaprepitant (a neurokinin-1 receptor antagonist), and granisetron (a serotonin 5-HT3 receptor antagonist). Together, they target different pathways involved in chemotherapy-induced nausea and vomiting. Clinical studies have shown that this three-drug combination is effective in preventing both acute (0-24 hours) and delayed (24-120 hours) phases of CINV. In one randomized study comparing palonosetron versus granisetron (both combined with dexamethasone and fosaprepitant), the complete response rates were similar between the two 5-HT3 antagonists when used in this three-drug regimen[1]. The typical dosing regimen includes: - Fosaprepitant: 150 mg IV on day 1 - Granisetron: 1 mg IV on day 1 - Dexamethasone: 12 mg orally on day 1, followed by 8 mg orally on days 2 and 3 This combination represents the current standard of care for preventing CINV in patients receiving highly emetogenic chemotherapy, with efficacy demonstrated in multiple clinical trials.